AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. The new SKYRIZI 150 mg pen comes with audible cues to help guide the administration process and an indicator to signal when administration is complete.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. The new SKYRIZI 150 mg pen comes with audible cues to help guide the administration process and an indicator to signal when administration is complete.

RTTNews | Aug 9, 2021 08:59AM EDT

08:58 Monday, August 9, 2021 (RTTNews.com) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. The new SKYRIZI 150 mg pen comes with audible cues to help guide the administration process and an indicator to signal when administration is complete.

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AbbVie noted that SKYRIZI is part of a collaboration with Boehringer Ingelheim, with the company leading development and commercialization globally.

Read the original article on RTTNews ( https://www.rttnews.com/3217345/abbvie-launches-skyrizi-as-single-dose-150-mg-injection-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved